1 Antihemophilic Factor Drug Market Overview 1.1 Product Overview and Scope of Antihemophilic Factor Drug 1.2 Antihemophilic Factor Drug Segment by Type 1.2.1 Global Antihemophilic Factor Drug Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 250 IU 1.2.3 500 IU 1.2.4 1000 IU 1.2.5 1500 IU 1.2.6 2000 IU 1.2.7 3000 IU 1.2.8 4000 IU 1.2.9 Other potencies 1.3 Antihemophilic Factor Drug Segment by Application 1.3.1 Global Antihemophilic Factor Drug Sales Comparison by Application: (2021-2027) 1.3.2 Adult 1.3.3 Pediatric 1.4 Global Antihemophilic Factor Drug Market Size Estimates and Forecasts 1.4.1 Global Antihemophilic Factor Drug Revenue 2016-2027 1.4.2 Global Antihemophilic Factor Drug Sales 2016-2027 1.4.3 Antihemophilic Factor Drug Market Size by Region: 2016 Versus 2021 Versus 2027 2 Antihemophilic Factor Drug Market Competition by Manufacturers 2.1 Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2016-2021) 2.2 Global Antihemophilic Factor Drug Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Antihemophilic Factor Drug Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Antihemophilic Factor Drug Manufacturing Sites, Area Served, Product Type 2.5 Antihemophilic Factor Drug Market Competitive Situation and Trends 2.5.1 Antihemophilic Factor Drug Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Antihemophilic Factor Drug Players Market Share by Revenue 2.5.3 Global Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Antihemophilic Factor Drug Retrospective Market Scenario by Region 3.1 Global Antihemophilic Factor Drug Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Antihemophilic Factor Drug Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Antihemophilic Factor Drug Market Facts & Figures by Country 3.3.1 North America Antihemophilic Factor Drug Sales by Country 3.3.2 North America Antihemophilic Factor Drug Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Antihemophilic Factor Drug Market Facts & Figures by Country 3.4.1 Europe Antihemophilic Factor Drug Sales by Country 3.4.2 Europe Antihemophilic Factor Drug Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Antihemophilic Factor Drug Market Facts & Figures by Region 3.5.1 Asia Pacific Antihemophilic Factor Drug Sales by Region 3.5.2 Asia Pacific Antihemophilic Factor Drug Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Antihemophilic Factor Drug Market Facts & Figures by Country 3.6.1 Latin America Antihemophilic Factor Drug Sales by Country 3.6.2 Latin America Antihemophilic Factor Drug Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Antihemophilic Factor Drug Market Facts & Figures by Country 3.7.1 Middle East and Africa Antihemophilic Factor Drug Sales by Country 3.7.2 Middle East and Africa Antihemophilic Factor Drug Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Antihemophilic Factor Drug Historic Market Analysis by Type 4.1 Global Antihemophilic Factor Drug Sales Market Share by Type (2016-2021) 4.2 Global Antihemophilic Factor Drug Revenue Market Share by Type (2016-2021) 4.3 Global Antihemophilic Factor Drug Price by Type (2016-2021) 5 Global Antihemophilic Factor Drug Historic Market Analysis by Application 5.1 Global Antihemophilic Factor Drug Sales Market Share by Application (2016-2021) 5.2 Global Antihemophilic Factor Drug Revenue Market Share by Application (2016-2021) 5.3 Global Antihemophilic Factor Drug Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Bayer 6.1.1 Bayer Corporation Information 6.1.2 Bayer Description and Business Overview 6.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Bayer Antihemophilic Factor Drug Product Portfolio 6.1.5 Bayer Recent Developments/Updates 6.2 Takeda 6.2.1 Takeda Corporation Information 6.2.2 Takeda Description and Business Overview 6.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Takeda Antihemophilic Factor Drug Product Portfolio 6.2.5 Takeda Recent Developments/Updates 6.3 Novo Nordisk 6.3.1 Novo Nordisk Corporation Information 6.3.2 Novo Nordisk Description and Business Overview 6.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Novo Nordisk Antihemophilic Factor Drug Product Portfolio 6.3.5 Novo Nordisk Recent Developments/Updates 6.4 Pfizer 6.4.1 Pfizer Corporation Information 6.4.2 Pfizer Description and Business Overview 6.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Pfizer Antihemophilic Factor Drug Product Portfolio 6.4.5 Pfizer Recent Developments/Updates 6.5 Grifols 6.5.1 Grifols Corporation Information 6.5.2 Grifols Description and Business Overview 6.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Grifols Antihemophilic Factor Drug Product Portfolio 6.5.5 Grifols Recent Developments/Updates 6.6 CSL Behring 6.6.1 CSL Behring Corporation Information 6.6.2 CSL Behring Description and Business Overview 6.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.6.4 CSL Behring Antihemophilic Factor Drug Product Portfolio 6.6.5 CSL Behring Recent Developments/Updates 6.7 Sanofi 6.6.1 Sanofi Corporation Information 6.6.2 Sanofi Description and Business Overview 6.6.3 Sanofi Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Sanofi Antihemophilic Factor Drug Product Portfolio 6.7.5 Sanofi Recent Developments/Updates 6.8 Cigna 6.8.1 Cigna Corporation Information 6.8.2 Cigna Description and Business Overview 6.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Cigna Antihemophilic Factor Drug Product Portfolio 6.8.5 Cigna Recent Developments/Updates 6.9 Octapharma 6.9.1 Octapharma Corporation Information 6.9.2 Octapharma Description and Business Overview 6.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Octapharma Antihemophilic Factor Drug Product Portfolio 6.9.5 Octapharma Recent Developments/Updates 6.10 GC Pharma 6.10.1 GC Pharma Corporation Information 6.10.2 GC Pharma Description and Business Overview 6.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.10.4 GC Pharma Antihemophilic Factor Drug Product Portfolio 6.10.5 GC Pharma Recent Developments/Updates 6.11 Hualan Biological Engineering 6.11.1 Hualan Biological Engineering Corporation Information 6.11.2 Hualan Biological Engineering Antihemophilic Factor Drug Description and Business Overview 6.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Portfolio 6.11.5 Hualan Biological Engineering Recent Developments/Updates 6.12 Shanghai RAAS blood products 6.12.1 Shanghai RAAS blood products Corporation Information 6.12.2 Shanghai RAAS blood products Antihemophilic Factor Drug Description and Business Overview 6.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2016-2021) 6.12.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Portfolio 6.12.5 Shanghai RAAS blood products Recent Developments/Updates 7 Antihemophilic Factor Drug Manufacturing Cost Analysis 7.1 Antihemophilic Factor Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Antihemophilic Factor Drug 7.4 Antihemophilic Factor Drug Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Antihemophilic Factor Drug Distributors List 8.3 Antihemophilic Factor Drug Customers 9 Antihemophilic Factor Drug Market Dynamics 9.1 Antihemophilic Factor Drug Industry Trends 9.2 Antihemophilic Factor Drug Growth Drivers 9.3 Antihemophilic Factor Drug Market Challenges 9.4 Antihemophilic Factor Drug Market Restraints 10 Global Market Forecast 10.1 Antihemophilic Factor Drug Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Antihemophilic Factor Drug by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Antihemophilic Factor Drug by Type (2022-2027) 10.2 Antihemophilic Factor Drug Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Antihemophilic Factor Drug by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Antihemophilic Factor Drug by Application (2022-2027) 10.3 Antihemophilic Factor Drug Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Antihemophilic Factor Drug by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Antihemophilic Factor Drug by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Antihemophilic Factor Drug Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Antihemophilic Factor Drug Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Antihemophilic Factor Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Antihemophilic Factor Drug Covered in This Study Table 5. Global Antihemophilic Factor Drug Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2016-2021) Table 7. Global Antihemophilic Factor Drug Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Antihemophilic Factor Drug Average Price (USD/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Antihemophilic Factor Drug Manufacturing Sites and Area Served Table 11. Manufacturers Antihemophilic Factor Drug Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antihemophilic Factor Drug as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Antihemophilic Factor Drug Sales by Region (2016-2021) & (K Units) Table 16. Global Antihemophilic Factor Drug Sales Market Share by Region (2016-2021) Table 17. Global Antihemophilic Factor Drug Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Antihemophilic Factor Drug Sales by Country (2016-2021) & (K Units) Table 19. North America Antihemophilic Factor Drug Sales Market Share by Country (2016-2021) Table 20. North America Antihemophilic Factor Drug Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Antihemophilic Factor Drug Revenue Market Share by Country (2016-2021) Table 22. Europe Antihemophilic Factor Drug Sales by Country (2016-2021) & (K Units) Table 23. Europe Antihemophilic Factor Drug Sales Market Share by Country (2016-2021) Table 24. Europe Antihemophilic Factor Drug Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Antihemophilic Factor Drug Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Antihemophilic Factor Drug Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Antihemophilic Factor Drug Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Antihemophilic Factor Drug Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Antihemophilic Factor Drug Revenue Market Share by Region (2016-2021) Table 30. Latin America Antihemophilic Factor Drug Sales by Country (2016-2021) & (K Units) Table 31. Latin America Antihemophilic Factor Drug Sales Market Share by Country (2016-2021) Table 32. Latin America Antihemophilic Factor Drug Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Antihemophilic Factor Drug Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Antihemophilic Factor Drug Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Antihemophilic Factor Drug Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Antihemophilic Factor Drug Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Antihemophilic Factor Drug Revenue Market Share by Country (2016-2021) Table 38. Global Antihemophilic Factor Drug Sales (K Units) by Type (2016-2021) Table 39. Global Antihemophilic Factor Drug Sales Market Share by Type (2016-2021) Table 40. Global Antihemophilic Factor Drug Revenue (Million US$) by Type (2016-2021) Table 41. Global Antihemophilic Factor Drug Revenue Share by Type (2016-2021) Table 42. Global Antihemophilic Factor Drug Price (USD/Unit) by Type (2016-2021) Table 43. Global Antihemophilic Factor Drug Sales (K Units) by Application (2016-2021) Table 44. Global Antihemophilic Factor Drug Sales Market Share by Application (2016-2021) Table 45. Global Antihemophilic Factor Drug Revenue (Million US$) by Application (2016-2021) Table 46. Global Antihemophilic Factor Drug Revenue Share by Application (2016-2021) Table 47. Global Antihemophilic Factor Drug Price (USD/Unit) by Application (2016-2021) Table 48. Bayer Corporation Information Table 49. Bayer Description and Business Overview Table 50. Bayer Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 51. Bayer Antihemophilic Factor Drug Product Table 52. Bayer Recent Developments/Updates Table 53. Takeda Corporation Information Table 54. Takeda Description and Business Overview Table 55. Takeda Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 56. Takeda Antihemophilic Factor Drug Product Table 57. Takeda Recent Developments/Updates Table 58. Novo Nordisk Corporation Information Table 59. Novo Nordisk Description and Business Overview Table 60. Novo Nordisk Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 61. Novo Nordisk Antihemophilic Factor Drug Product Table 62. Novo Nordisk Recent Developments/Updates Table 63. Pfizer Corporation Information Table 64. Pfizer Description and Business Overview Table 65. Pfizer Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 66. Pfizer Antihemophilic Factor Drug Product Table 67. Pfizer Recent Developments/Updates Table 68. Grifols Corporation Information Table 69. Grifols Description and Business Overview Table 70. Grifols Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 71. Grifols Antihemophilic Factor Drug Product Table 72. Grifols Recent Developments/Updates Table 73. CSL Behring Corporation Information Table 74. CSL Behring Description and Business Overview Table 75. CSL Behring Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 76. CSL Behring Antihemophilic Factor Drug Product Table 77. CSL Behring Recent Developments/Updates Table 78. Sanofi Corporation Information Table 79. Sanofi Description and Business Overview Table 80. Sanofi Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 81. Sanofi Antihemophilic Factor Drug Product Table 82. Sanofi Recent Developments/Updates Table 83. Cigna Corporation Information Table 84. Cigna Description and Business Overview Table 85. Cigna Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 86. Cigna Antihemophilic Factor Drug Product Table 87. Cigna Recent Developments/Updates Table 88. Octapharma Corporation Information Table 89. Octapharma Description and Business Overview Table 90. Octapharma Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 91. Octapharma Antihemophilic Factor Drug Product Table 92. Octapharma Recent Developments/Updates Table 93. GC Pharma Corporation Information Table 94. GC Pharma Description and Business Overview Table 95. GC Pharma Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 96. GC Pharma Antihemophilic Factor Drug Product Table 97. GC Pharma Recent Developments/Updates Table 98. Hualan Biological Engineering Corporation Information Table 99. Hualan Biological Engineering Description and Business Overview Table 100. Hualan Biological Engineering Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 101. Hualan Biological Engineering Antihemophilic Factor Drug Product Table 102. Hualan Biological Engineering Recent Developments/Updates Table 103. Shanghai RAAS blood products Corporation Information Table 104. Shanghai RAAS blood products Description and Business Overview Table 105. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 106. Shanghai RAAS blood products Antihemophilic Factor Drug Product Table 107. Shanghai RAAS blood products Recent Developments/Updates Table 108. Production Base and Market Concentration Rate of Raw Material Table 109. Key Suppliers of Raw Materials Table 110. Antihemophilic Factor Drug Distributors List Table 111. Antihemophilic Factor Drug Customers List Table 112. Antihemophilic Factor Drug Market Trends Table 113. Antihemophilic Factor Drug Growth Drivers Table 114. Antihemophilic Factor Drug Market Challenges Table 115. Antihemophilic Factor Drug Market Restraints Table 116. Global Antihemophilic Factor Drug Sales Forecast by Type (2022-2027) & (K Units) Table 117. Global Antihemophilic Factor Drug Sales Market Share Forecast by Type (2022-2027) Table 118. Global Antihemophilic Factor Drug Revenue Forecast by Type (2022-2027) & (US$ Million) Table 119. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Type (2022-2027) Table 120. Global Antihemophilic Factor Drug Sales Forecast by Application (2022-2027) & (K Units) Table 121. Global Antihemophilic Factor Drug Sales Market Share Forecast by Application (2022-2027) Table 122. Global Antihemophilic Factor Drug Revenue Forecast by Application (2022-2027) & (US$ Million) Table 123. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Application (2022-2027) Table 124. Global Antihemophilic Factor Drug Sales Forecast by Region (2022-2027) & (K Units) Table 125. Global Antihemophilic Factor Drug Sales Market Share Forecast by Region (2022-2027) Table 126. Global Antihemophilic Factor Drug Revenue Forecast by Region (2022-2027) & (US$ Million) Table 127. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Region (2022-2027) Table 128. Research Programs/Design for This Report Table 129. Key Data Information from Secondary Sources Table 130. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Antihemophilic Factor Drug Figure 2. Global Antihemophilic Factor Drug Market Share by Type in 2020 & 2027 Figure 3. 250 IU Product Picture Figure 4. 500 IU Product Picture Figure 5. 1000 IU Product Picture Figure 6. 1500 IU Product Picture Figure 7. 2000 IU Product Picture Figure 8. 3000 IU Product Picture Figure 9. 4000 IU Product Picture Figure 10. Other potencies Product Picture Figure 11. Global Antihemophilic Factor Drug Market Share by Application in 2020 & 2027 Figure 12. Adult Figure 13. Pediatric Figure 14. Global Antihemophilic Factor Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 15. Global Antihemophilic Factor Drug Market Size 2016-2027 (US$ Million) Figure 16. Global Antihemophilic Factor Drug Sales 2016-2027 (K Units) Figure 17. Global Antihemophilic Factor Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 18. Antihemophilic Factor Drug Sales Share by Manufacturers in 2020 Figure 19. Global Antihemophilic Factor Drug Revenue Share by Manufacturers in 2020 Figure 20. The Global 5 and 10 Largest Antihemophilic Factor Drug Players: Market Share by Revenue in 2020 Figure 21. Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 22. Global Antihemophilic Factor Drug Sales Market Share by Region (2016-2021) Figure 23. Global Antihemophilic Factor Drug Sales Market Share by Region in 2020 Figure 24. Global Antihemophilic Factor Drug Revenue Market Share by Region (2016-2021) Figure 25. Global Antihemophilic Factor Drug Revenue Market Share by Region in 2020 Figure 26. U.S. Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Canada Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Germany Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. France Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. U.K. Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Italy Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. Russia Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. China Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Japan Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. South Korea Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. India Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Australia Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Taiwan Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Indonesia Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Thailand Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Malaysia Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Philippines Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Vietnam Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Mexico Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Brazil Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Argentina Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Turkey Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. Saudi Arabia Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 49. U.A.E Antihemophilic Factor Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 50. Sales Market Share of Antihemophilic Factor Drug by Type (2016-2021) Figure 51. Sales Market Share of Antihemophilic Factor Drug by Application (2016-2021) Figure 52. Sales Market Share of Antihemophilic Factor Drug by Application in 2020 Figure 53. Revenue Share of Antihemophilic Factor Drug by Application (2016-2021) Figure 54. Revenue Share of Antihemophilic Factor Drug by Application in 2020 Figure 55. Manufacturing Cost Structure of Antihemophilic Factor Drug Figure 56. Manufacturing Process Analysis of Antihemophilic Factor Drug Figure 57. Antihemophilic Factor Drug Industrial Chain Analysis Figure 58. Channels of Distribution Figure 59. Distributors Profiles Figure 60. Bottom-up and Top-down Approaches for This Report Figure 61. Data Triangulation Figure 62. Key Executives Interviewed

Bayer Takeda Novo Nordisk Pfizer Grifols CSL Behring Sanofi Cigna Octapharma GC Pharma Hualan Biological Engineering Shanghai RAAS blood products